Standard BioTools Inc. (LAB) Stock Price & Analysis
Standard BioTools Inc. (LAB) closed at USD 0.66 on Thursday, October 15, 2026, up 4.18% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.63; the Oct 15, 2026 session ranged USD 0.63–0.67 on volume of 485,713 shares. Market capitalization is $258.47M, with a 52-week range of USD 0.63–1.72 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LAB.md
Key facts (LAB)
- Last four reported quarters (through Jun 30, 2026): revenue $84.6M, net income $84.9M (100.4% margin), free cash flow -$82.6M (SEC filings).
- Valuation: P/E 3.0x.
- 1 of 80 tracked superinvestors hold LAB (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Hold (mean 3.00 on a 1–5 scale) (1 analysts), mean target USD 1.35 (range 1.35–1.35).
- Total return with dividends: 1Y -48.8% vs S&P 500 +18.1%; 5Y -87.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.02, revenue estimate $18.8M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LAB)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $131M | $97.9M | $106M | $91.0M | $85.3M | $84.6M |
| Gross profit | — | $37.1M | $50.5M | $44.9M | $42.5M | — |
| Operating income | -$67.5M | -$116M | -$76.6M | -$127M | -$110M | -$95.5M |
| Net income | -$59.2M | -$190M | -$74.7M | -$139M | -$74.9M | $84.9M |
| EPS (diluted) | -$0.78 | -$2.43 | -$0.94 | -$0.52 | -$0.20 | — |
| Free cash flow | -$57.3M | -$93.2M | -$46.1M | -$152M | -$82.6M | -$82.6M |
| Gross margin | — | 37.8% | 47.4% | 49.3% | 49.9% | — |
| Operating margin | -51.7% | -118.6% | -72.0% | -140.1% | -129.2% | -112.8% |
| Net margin | -45.4% | -194.1% | -70.2% | -152.6% | -87.8% | 100.4% |
| Revenue growth | -5.5% | -25.0% | +8.6% | -14.4% | -6.2% | — |
| Cash + short-term investments | $29.5M | $167M | $115M | $293M | $188M | — |
| Total debt | — | $64.9M | $63.5M | $299K | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (LAB)
P/E 3.0x · P/S 3.1x · P/B 0.5x · FCF yield -31.95% · Earnings yield 32.85%
Superinvestors (SEC 13F-HR, Q2 2026) (LAB)
1 of 80 tracked investors hold LAB. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.14% | $48.3M | Unchanged |
Analysts (LAB)
Consensus Hold (mean 3.00 on a 1–5 scale), 1 analysts; mean target USD 1.35 (low 1.35, high 1.35).
Total return (dividends reinvested) (LAB)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -48.8% | -87.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -49.0% | -34.1% |
| Volatility (annualized) | 71.3% | 72.9% |
| Max drawdown | -62.5% (Dec 2025→Oct 2026) | -88.0% (Oct 2021→Aug 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 0.66 |
|---|---|
| Change | ▲ 4.18% (up) |
| Previous Close | USD 0.63 |
| Open | USD 0.63 |
| Day Range | USD 0.63 – 0.67 |
| 52-Week Range | USD 0.63 – 1.72 |
| Volume | 485,713 shares |
| Market Cap | $258.47M |
| Exchange | NMS |
Technical Analysis (LAB)
Nexqual's technical model rates LAB "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.07 (neutral) |
| vs SMA50 | Below (USD 0.7) |
| MACD | -0.02 (negative) |
Analyst Ratings (LAB)
Wall Street analysts rate LAB "Hold" based on 1 analysts, with a mean price target of USD 1.35 (range USD 1.35–1.35), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 1.35 |
| High Target | USD 1.35 |
| Low Target | USD 1.35 |
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (LAB)
| Next Earnings Date | 2026-11-03 |
|---|---|
| Revenue Estimate | $18.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.06 vs est -0.03 ▼ miss |
| 2026-03-31 | USD -0.02 vs est -0.02 ▲ beat |
| 2025-12-31 | USD 0.07 vs est -0.03 ▲ beat |
| 2025-09-30 | USD -0.04 vs est -0.02 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (LAB)
| Total Revenue | $84.60M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -7.60% |
| Gross Margin | +50.49% |
| Operating Margin | -38.94% |
| Profit Margin | +100.36% |
| ROE | -11.18% |
| Debt / Equity | 0.05 |
| Current Ratio | 9.1 |
| Total Cash | $476.72M |
| Total Debt | $28.09M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$82.65M (-96.9% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (LAB)
Nexqual rates Standard BioTools Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -51% YoY (annual), sharp decline |
|---|---|
| Profitability | Mixed — Gross margin 50%, operating -39% |
| Balance Sheet | Strong — $477M cash vs $28M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$83M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -11%, ROA -6.6% |
Ownership (LAB)
| Insider Ownership | +1.84% |
|---|---|
| Institutional Ownership | +75.79% |
| Shares Outstanding | 392.58M |
| Float | 184.62M |
| Short % of Float | +1.06% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (LAB)
Standard BioTools Inc. is led by Michael Egholm (age 62), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO & Director | Michael Egholm (age 62) |
|---|---|
| Chief Financial Officer | Hanjoon Kim (age 54) |
| Vice President of Investor Relations | John Graziano |
| Senior Vice President of Global Operations | Anders Davas |
Major Backers & Investors (LAB)
Notable institutional backers of Standard BioTools Inc. include Casdin Capital, LLC, Viking Global, MAK Capital One LLC, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Casdin Capital, LLC | 22.62% |
| Viking Global | 14.94% |
| MAK Capital One LLC | 7.34% |
| Long Focus Capital Management, LLC | 5.99% |
| Neuberger Berman Group, LLC | 1.52% |
| Hollow Brook Wealth Management LLC | 1.4% |
| Qube Research & Technologies Ltd | 1.23% |
| Royce & Associates LP | 1.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.71% |
| BlackRock | 2.81% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc | USD 61.36 | ▲ 4.98% |
| ALMR | Alamar Biosciences, Inc. | USD 27.42 | ▲ 16.58% |
| INSP | Inspire Medical Systems, Inc. | USD 70.12 | ▲ 1.83% |
| BFLY | Butterfly Network, Inc. | USD 7.85 | ▼ 3.09% |
| AXGN | AxoGen, Inc. | USD 35.63 | ▼ 1.49% |
| UFPT | UFP Technologies, Inc. | USD 297.19 | ▲ 0.99% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt